Rosaandco.com - Rosa And Co. Llc Company News Section
Rosa And Co. Llc Information
751 Laurel St., Ste. 127,
San Carlos, CA 94070
Rosa informs our customer%u2019s most critical decisions %u2013 from preclinical through clinical development %u2013 with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/ pharmacodynamic models and Rosa%u2019s innovative PhysioPD models. With these approaches, Rosa%u2019s clients collaborate in model creation and testing, retain the final model, and acquire the ability to use and interpret it. Rosa%u2019s staff have unparalleled experience in drug-disease modeling and simulation (M&S), with decades of professional experience.
The Model Qualification Method is a rigorous, systematic analysis of model relevance, uncertainty, variability, and consistency with data to ensure drug discovery/development models are "fit for purpose".
Alliance combines innovative exploratory study design, leading in silico drug development capabilities, and a global licensing network to increase the value of emerging company portfolios and address pipeline gaps for established drug manufacturers.
You are invited to attend Dr. Goburru's webinar The "Learn & Apply" Paradigm in Drug Development on April 18, 2011 at 1:00 pm EST (GMT -5:00) (www.rosaandco.com/webinar). This talk will summarize the state of the art in applying drug-disease-trial modeling to decision-making processes in drug development.
In collaboration with its clients, Lithera, MediciNova, Pfizer, Vitalea, Rosa & Co will present six posters at the 2011 American College on Pharmacometrics in San Diego, CA on April 4, 2011. The posters describe the use of drug-disease modeling in pharmaceutical development.
Rosa & Co. LLC, announce the appointment of Sharan A. Pagano, Vice President, Scientific Alliances, responsible for worldwide sales and account development, and the opening of Rosa's new Boston, MA-area office.
In collaboration with Vitalea Science, Inc., Rosa & Co will present the first clinical study of UDCA pharmacokinetics in neonates at the 2011 American Society for Clinical Pharmacology and Therapeutics in Dallas, TX entitled "Compartmental Analysis of Urosodiol PK in Neonates using AMS " at 8:00 am on March 4, 2011.